$1.3B Keytru­da wind­fall will be used to ac­cel­er­ate trans­la­tion­al drug R&D in the UK

Trans­la­tion­al re­search in the UK is get­ting a ma­jor boost.

The non­prof­it LifeArc has struck a deal to sell a large block of its Keytru­da roy­al­ties to a pen­sion firm for $1.3 bil­lion it will now use to sup­port sci­en­tists at work de­vel­op­ing new drugs and de­vices. The rich UK R&D scene has been a fer­tile ground for ear­ly-stage work. And this wind­fall of block­buster cash will now bol­ster LifeArc’s work in the field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER